An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period.
Publication/Presentation Date
11-1-2019
Volume
12
Issue
11
First Page
13
Last Page
18
ISSN
1941-2789
Published In/Presented At
Del Rosso, J. Q., Stein Gold, L., Segal, J., & Zaenglein, A. L. (2019). An Open-label, Phase IV Study Evaluating Lidose-isotretinoin Administered without Food in Patients with Severe Recalcitrant Nodular Acne: Low Relapse Rates Observed Over the 104-week Post-treatment Period. The Journal of clinical and aesthetic dermatology, 12(11), 13–18.
Disciplines
Medicine and Health Sciences
PubMedID
32038751
Department(s)
Department of Medicine
Document Type
Article
COinS